210 related articles for article (PubMed ID: 33626352)
1. Inhibition of FGF10-ERK signal activation suppresses intraductal papillary neoplasm of the bile duct and its associated carcinomas.
Tomita H; Tanaka K; Hirata A; Okada H; Imai H; Shirakami Y; Ohnishi K; Sugie S; Aoki H; Hatano Y; Noguchi K; Kanayama T; Niwa A; Suzui N; Miyazaki T; Tanaka T; Akiyama H; Shimizu M; Yoshida K; Hara A
Cell Rep; 2021 Feb; 34(8):108772. PubMed ID: 33626352
[TBL] [Abstract][Full Text] [Related]
2. Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis.
Goeppert B; Stichel D; Toth R; Fritzsche S; Loeffler MA; Schlitter AM; Neumann O; Assenov Y; Vogel MN; Mehrabi A; Hoffmann K; Köhler B; Springfeld C; Weichenhan D; Plass C; Esposito I; Schirmacher P; von Deimling A; Roessler S
Gut; 2022 Feb; 71(2):391-401. PubMed ID: 33468537
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological characterization of so-called "cholangiocarcinoma with intraductal papillary growth" with respect to "intraductal papillary neoplasm of bile duct (IPNB)".
Nakanuma Y; Sato Y; Ojima H; Kanai Y; Aishima S; Yamamoto M; Ariizumi S; Furukawa T; Hayashi H; Unno M; Ohta T;
Int J Clin Exp Pathol; 2014; 7(6):3112-22. PubMed ID: 25031730
[TBL] [Abstract][Full Text] [Related]
4. Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas.
Pu X; Ye Q; Cai J; Yang X; Fu Y; Fan X; Wu H; Chen J; Qiu Y; Yue S
Cell Death Dis; 2021 Mar; 12(3):256. PubMed ID: 33692336
[TBL] [Abstract][Full Text] [Related]
5. Targeted next-generation sequencing identifies distinct clinicopathologic and molecular entities of intraductal papillary neoplasms of the bile duct.
Yang CY; Huang WJ; Tsai JH; Cheng A; Chen CC; Hsu HP; Jeng YM
Mod Pathol; 2019 Nov; 32(11):1637-1645. PubMed ID: 31231124
[TBL] [Abstract][Full Text] [Related]
6. Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways.
Schlitter AM; Born D; Bettstetter M; Specht K; Kim-Fuchs C; Riener MO; Jeliazkova P; Sipos B; Siveke JT; Terris B; Zen Y; Schuster T; Höfler H; Perren A; Klöppel G; Esposito I
Mod Pathol; 2014 Jan; 27(1):73-86. PubMed ID: 23828315
[TBL] [Abstract][Full Text] [Related]
7. A statement by the Japan-Korea expert pathologists for future clinicopathological and molecular analyses toward consensus building of intraductal papillary neoplasm of the bile duct through several opinions at the present stage.
Nakanuma Y; Jang KT; Fukushima N; Furukawa T; Hong SM; Kim H; Lee KB; Zen Y; Jang JY; Kubota K
J Hepatobiliary Pancreat Sci; 2018 Mar; 25(3):181-187. PubMed ID: 29272078
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic performance of CT and MRI in distinguishing intraductal papillary neoplasm of the bile duct from cholangiocarcinoma with intraductal papillary growth.
Liu Y; Zhong X; Yan L; Zheng J; Liu Z; Liang C
Eur Radiol; 2015 Jul; 25(7):1967-74. PubMed ID: 25716939
[TBL] [Abstract][Full Text] [Related]
9. 2,3,7,8-Tetrachlorodibenzo-p-dioxin inhibits fibroblast growth factor 10-induced prostatic bud formation in mouse urogenital sinus.
Vezina CM; Hardin HA; Moore RW; Allgeier SH; Peterson RE
Toxicol Sci; 2010 Jan; 113(1):198-206. PubMed ID: 19805408
[TBL] [Abstract][Full Text] [Related]
10. FGF10/FGFR2 Signaling: Therapeutically Targetable Vulnerability in Ligand-responsive Cholangiocarcinoma Cells.
Oeurn K; Jusakul A; Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Kongpetch S
In Vivo; 2023; 37(4):1628-1637. PubMed ID: 37369494
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
Graham RP; Barr Fritcher EG; Pestova E; Schulz J; Sitailo LA; Vasmatzis G; Murphy SJ; McWilliams RR; Hart SN; Halling KC; Roberts LR; Gores GJ; Couch FJ; Zhang L; Borad MJ; Kipp BR
Hum Pathol; 2014 Aug; 45(8):1630-8. PubMed ID: 24837095
[TBL] [Abstract][Full Text] [Related]
12. [Intraductal papillary neoplasms of the bile duct (IPNB). Diagnostic criteria, carcinogenesis and differential diagnostics].
Schlitter AM; Klöppel G; Esposito I
Pathologe; 2013 Nov; 34 Suppl 2():235-40. PubMed ID: 24196621
[TBL] [Abstract][Full Text] [Related]
13. Expression of cell cycle-related molecules in biliary premalignant lesions: biliary intraepithelial neoplasia and biliary intraductal papillary neoplasm.
Nakanishi Y; Zen Y; Kondo S; Itoh T; Itatsu K; Nakanuma Y
Hum Pathol; 2008 Aug; 39(8):1153-61. PubMed ID: 18495210
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of Preoperative
Ikeno Y; Seo S; Yamamoto G; Nakamoto Y; Uemoto Y; Fuji H; Yoshino K; Yoh T; Taura K; Uemoto S
Anticancer Res; 2018 Jun; 38(6):3677-3682. PubMed ID: 29848727
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis of the progression of flat and papillary preneoplastic lesions in intrahepatic cholangiocarcinogenesis in hepatolithiasis.
Itatsu K; Zen Y; Ohira S; Ishikawa A; Sato Y; Harada K; Ikeda H; Sasaki M; Nimura Y; Nakanuma Y
Liver Int; 2007 Nov; 27(9):1174-84. PubMed ID: 17919228
[TBL] [Abstract][Full Text] [Related]
16. RNF43 mutation frequently occurs with GNAS mutation and mucin hypersecretion in intraductal papillary neoplasms of the bile duct.
Tsai JH; Liau JY; Yuan CT; Cheng ML; Yuan RH; Jeng YM
Histopathology; 2017 Apr; 70(5):756-765. PubMed ID: 27864998
[TBL] [Abstract][Full Text] [Related]
17. Intraductal papillary neoplasms of the bile duct consist of two distinct types specifically associated with clinicopathological features and molecular phenotypes.
Aoki Y; Mizuma M; Hata T; Aoki T; Omori Y; Ono Y; Mizukami Y; Unno M; Furukawa T
J Pathol; 2020 May; 251(1):38-48. PubMed ID: 32100878
[TBL] [Abstract][Full Text] [Related]
18. A Mouse Model of Cholangiocarcinoma Uncovers a Role for Tensin-4 in Tumor Progression.
Di-Luoffo M; Pirenne S; Saandi T; Loriot A; Gérard C; Dauguet N; Manzano-Núñez F; Alves Souza Carvalhais N; Lamoline F; Cordi S; Konobrocka K; De Greef V; Komuta M; Halder G; Jacquemin P; Lemaigre FP
Hepatology; 2021 Sep; 74(3):1445-1460. PubMed ID: 33768568
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of surgery for 2010 WHO classification-based intraductal papillary neoplasm of the bile duct: Case-control study of a single Japanese institution's experience with special attention to mucin expression patterns.
Harada F; Matsuyama R; Mori R; Kumamoto T; Morioka D; Taguri M; Yamanaka S; Endo I
Eur J Surg Oncol; 2019 May; 45(5):761-768. PubMed ID: 30389302
[TBL] [Abstract][Full Text] [Related]
20. Comparative clinicopathological study of biliary intraductal papillary neoplasms and papillary cholangiocarcinomas.
Fujikura K; Fukumoto T; Ajiki T; Otani K; Kanzawa M; Akita M; Kido M; Ku Y; Itoh T; Zen Y
Histopathology; 2016 Dec; 69(6):950-961. PubMed ID: 27410028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
